Answer a few questions using Lilly Trial Match to find which Lilly trials may be the best fit for you or your loved one.
Answer a few questions using Lilly Trial Match to find which Lilly trials may be the best fit for you or your loved one.

Find a Lilly Clinical Trial

69  Enrolling
131  Total Trials
Pinned
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Enrolling
Conditions: Obesity
Trial Name
ATTAIN-1
Drugs: Orforglipron
Age
≥18
Phase
III
Pinned
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Enrolling
Conditions: Obesity, Overweight, Type 2 Diabetes
Trial Name
ATTAIN-2
Drugs: Orforglipron
Age
≥18
Phase
III
Pinned
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight a...
Enrolling
Conditions: Type 2 Diabetes, Overweight at Increased Cardiovascular Risk
Trial Name
ACHIEVE-4
Drugs: Orforglipron (LY3502970), Insulin Glargine
Age
≥18
Phase
III
Pinned
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Enrolling
Conditions: Obesity, Overweight and Cardiovascular Disease
Trial Name
TRIUMPH-3
Drugs: Retatrutide
Age
≥18
Phase
III
Pinned
A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrolling
Conditions: Heart Failure
Drugs: LY3540378
Age
≥18
Phase
II
Pinned
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Enrolling
Conditions: Obesity, Overweight, Type 2 Diabetes, Sleep Apnea
Trial Name
TRIUMPH-2
Drugs: Retatrutide
Age
≥18
Phase
III
Pinned
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Enrolling
Conditions: Obesity, Overweight, Osteoarthritis, Sleep Apnea
Trial Name
TRIUMPH-1
Drugs: Retatrutide
Age
≥18
Phase
III
Pinned
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
Enrolling
Conditions: Type 2 Diabetes
Trial Name
ACHIEVE-1
Drugs: Orforglipron
Age
≥18
Phase
III
Pinned
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
Enrolling
Conditions: Obesity, Overweight and Osteoarthritis of the Knee
Trial Name
TRIUMPH-4
Drugs: Retatrutide
Age
≥18
Phase
III
Pinned
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine (REBUILD-2)
Enrolling
Conditions: Migraine
Trial Name
REBUILD-2
Drugs: Galcanezumab
Age
12-17
Phase
III
Pinned
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
Enrolling
Conditions: Rheumatoid Arthritis
Drugs: LY3871801
Age
≥18
Phase
II
Pinned
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS1)
Enrolling
Conditions: Migraine
Trial Name
PIONEER-PEDS1
Drugs: lasmiditan (LY-573144)
Age
6-17
Phase
III
Pinned
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine (REBUILD-1)
Enrolling
Conditions: Migraine
Trial Name
REBUILD-1
Drugs: Galcanezumab
Age
6-17
Phase
III
Pinned
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Enrolling
Conditions: Alzheimer's Disease
Trial Name
TRAILRUNNER-ALZ 1
Drugs: Remternetug (LY3372993)
Age
60-85
Phase
III
Pinned
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
Enrolling
Conditions: Alzheimer's Disease
Drugs: donanemab
Age
60-85
Phase
III
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
Enrolling
Conditions: Gaucher Disease, Type 1
Trial Name
PROCEED
Drugs: LY3884961, an investigational gene therapy
Age
18-65
Phase
II
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PIKASSO-01)
Enrolling
Conditions: Breast Cancer, Advanced Solid Tumors
Trial Name
PIKASSO-01
Drugs: LOXO-783
Age
≥18
Phase
I
Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lym...
Enrolling
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Trial Name
BRUIN CLL-321
Drugs: Bendamustine, Idelalisib, LOXO-305, Rituximab
Age
≥18
Phase
III
A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3
Enrolling
Conditions: Bladder Cancer, Advanced Solid Tumors
Drugs: LOX-24350 / LOXO-435, Pembrolizumab
Age
≥18
Phase
I
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-1)
Enrolling
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADorable-1
Drugs: Lebrikizumab, Topical corticosteroid
Age
6-17
Phase
III
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Enrolling
Conditions: Hidradenitis Suppurativa
Drugs: Eltrekibart
Age
18-75
Phase
II
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)
Enrolling
Conditions: Breast Cancer
Trial Name
EMBER-4
Drugs: Anastrozole, Exemestane, Imlunestrant, Letrozole, Tamoxifen
Age
≥18
Phase
III
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata (BRAVE-AA1)
Enrolling
Conditions: Alopecia Areata (hair loss)
Trial Name
BRAVE-AA1
Drugs: Baricitinib
Age
18-70
Phase
III
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease
Enrolling
Conditions: Non-Alcoholic Fatty Liver Disease
Drugs: LY3849891
Age
18-70
Phase
I
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Enrolling
Conditions: Ewing's Sarcoma
Trial Name
CAMPFIRE
Drugs: Abemaciclib (LY2835219)
Age
1-39
Phase
II
A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function
Enrolling
Conditions: Hepatic Insufficiency
Drugs: Imlunestrant (LY3484356)
Age
≥18
Phase
I
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Rel...
Enrolling
Conditions: Obesity, Overweight
Drugs: Tirzepatide (LY3298176)
Age
≥18
Phase
III
A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction
Enrolling
Conditions: Heart Failure
Drugs: LY3461767
Age
18-80
Phase
I
A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events (KRAKEN)
Enrolling
Conditions: Lipoprotein Disorder
Trial Name
KRAKEN
Drugs: LY3473329
Age
≥40
Phase
II
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
Enrolling
Conditions: Diabetic Peripheral Neuropathy
Drugs: LY3556050
Age
≥18
Phase
II
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS)
Enrolling
Conditions: Alopecia Areata (hair loss)
Trial Name
BRAVE-AA-PEDS
Drugs: baricitinib
Age
6-17
Phase
III
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LU...
Enrolling
Conditions: Ulcerative Colitis
Trial Name
LUCENT 3
Drugs: Mirikizumab
Age
18-80
Phase
III
A Study of Baricitinib in Participants With Rheumatoid Arthritis (RA-BRANCH)
Enrolling
Conditions: Rheumatoid Arthritis
Trial Name
RA-BRANCH
Drugs: Baricitinib, TNF Inhibitor
Age
≥18
Phase
IV
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes (SURPASS-EARLY)
Enrolling
Conditions: Type 2 Diabetes
Trial Name
SURPASS-EARLY
Drugs: Antihyperglycemic medication, Tirzepatide
Age
≥18
Phase
IV
A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Derm...
Enrolling
Conditions: Atopic Dermatitis (Eczema )
Trial Name
ADmirable
Drugs: Lebrikizumab
Age
≥12
Phase
III
A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dup...
Enrolling
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADapt
Drugs: Lebrikizumab
Age
≥12
Phase
III
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
Enrolling
Conditions: Type 2 Diabetes
Trial Name
SURPASS-SWITCH
Drugs: Dulaglutide, Tirzepatide
Age
≥18
Phase
IV
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)
Enrolling
Conditions: Crohn's Disease
Trial Name
VIVID-2
Drugs: Mirikizumab
Age
≥18
Phase
III
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)
Enrolling
Conditions: Migraine
Trial Name
PIONEER-PEDS2
Drugs: lasmiditan (LY-573144)
Age
6-17
Phase
III
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)
Enrolling
Conditions: Non-Small Cell Lung Cancer
Trial Name
LIBRETTO-432
Drugs: Selpercatinib
Age
≥18
Phase
III
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to ...
Enrolling
Conditions: Prostate Cancer
Trial Name
CYCLONE 3
Drugs: Abemaciclib, Abiraterone, LY2835219, Prednisone, Prednisolone
Age
≥18
Phase
III
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advance...
Enrolling
Conditions: Breast Cancer
Trial Name
EMBER-3
Drugs: LY3484356, Exemestane, Fulvestrant, Imlunestrant, Abemaciclib
Age
≥18
Phase
III
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)
Enrolling
Conditions: Obesity
Trial Name
SURMOUNT-MMO
Drugs: Tirzepatide
Age
≥40
Phase
III
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Enrolling
Conditions: Type 2 Diabetes
Trial Name
ACHIEVE-3
Drugs: Orforglipron, Semaglutide
Age
≥18
Phase
III
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
Enrolling
Conditions: Atopic Dermatitis (Eczema)
Drugs: Ucenprubart
Age
18-70
Phase
II
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
Enrolling
Conditions: Type 2 Diabetes
Trial Name
ACHIEVE-J
Drugs: Orforglipron
Age
≥18
Phase
III
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT-URGE)
Enrolling
Conditions: Ulcerative Colitis
Trial Name
LUCENT-URGE
Drugs: Mirikizumab
Age
≥18
Phase
III
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
Enrolling
Conditions: Type 2 Diabetes, Obesity
Drugs: Tirzepatide (LY3298176)
Age
18-75
Phase
II
A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes (RescuiNGkids)
Enrolling
Conditions: Type 1 Diabetes
Trial Name
RescuiNGkids
Drugs: Glucagon Nasal Powder, Baqsimi, LY900018
Age
1-4
Phase
I
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (TREA...
Enrolling
Conditions: Obesity, Overweight, Chronic Kidney Disease with or without Type 2 Diabetes
Trial Name
TREASURE-CKD
Drugs: Tirzepatide
Age
≥18
Phase
II
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled Wit...
Enrolling
Conditions: Type 2 Diabetes
Trial Name
SURPASS-PEDS
Drugs: Tirzepatide
Age
10-18
Phase
III
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Enrolling
Conditions: Alzheimer's Disease
Trial Name
TRAILBLAZER-ALZ 3
Drugs: Donanemab, LY3002813
Age
65-80
Phase
III
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) ...
Enrolling
Conditions: Chronic Lymphocytic Leukemia, B-cell Leukemias, Small Lymphocytic Lymphomas
Trial Name
BRUIN-CLL-314
Drugs: Pirtobrutinib, Ibrutinib
Age
≥18
Phase
III
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lym...
Enrolling
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Trial Name
BRUIN CLL-322
Drugs: Pirtobrutinib, Rituximab, Venetoclax
Age
≥18
Phase
III
A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis
Enrolling
Conditions: Atopic Dermatitis (Eczema)
Drugs: LY3844583
Age
18-65
Phase
I
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
Enrolling
Conditions: Alzheimer's Disease
Drugs: Donanemab
Age
60-85
Phase
III
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-X)
Enrolling
Conditions: Juvenile Idiopathic Arthritis
Trial Name
JUVE-X
Drugs: Baricitinib
Age
1-18
Phase
III
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenil...
Enrolling
Conditions: Arthritis
Drugs: Ixekizumab, Adalimumab
Age
2-17
Phase
III
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors...
Enrolling
Conditions: Advanced Solid Tumors
Drugs: Abemaciclib, Irinotecan, Temozolomide, Dinutuximab and GM-CSF
Age
≤21
Phase
II
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Enrolling
Conditions: Crohn's Disease
Trial Name
SHINE-On
Drugs: Mirikizumab
Age
2-19
Phase
III
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
Enrolling
Conditions: Obesity
Trial Name
ATTAIN-J
Drugs: Orforglipron
Age
≥18
Phase
III
A Study of LY3502970 in Participants With Impaired and Normal Liver Function
Enrolling
Conditions: Hepatic Impairment, Healthy Participants
Drugs: Orforglipron
Age
18-80
Phase
I
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With sJIA
Enrolling
Conditions: Systemic Juvenile Idiopathic Arthritis
Drugs: Baricitinib
Age
1-17
Phase
III
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321)
Enrolling
Conditions: Mantle Cell Lymphoma
Trial Name
BRUIN-MCL-321
Drugs: Acalabrutinib, Ibrutinib, Pirtobrutinib, Zanubrutinib
Age
≥18
Phase
III
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Enrolling
Conditions: Lung Cancer, Advanced Solid Tumors
Drugs: LY3537982, Abemaciclib, Pembrolizumab, LY3295668, Cetuximab
Age
≥18
Phase
I
A Study of Baricitinib (LY3009104) in Children With COVID-19 (COV-BARRIER-PEDS) (COV-BARRIER)
Enrolling
Conditions: COVID-19
Trial Name
COV-BARRIER-PEDS
Drugs: Baricitinib, LY3009104
Age
2-18
Phase
III
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
Enrolling
Conditions: Lung Cancer, Thyroid Cancer
Trial Name
JUVE-BASIS
Drugs: LOXO-260
Age
≥12
Phase
I
A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus
Enrolling
Conditions: Type 1 Diabetes
Drugs: LY3532226
Age
18-70
Phase
I
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Smal...
Enrolling
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Trial Name
BRUIN CLL-313
Drugs: Bendamustine, Pirtobrutinib, Rituximab
Age
≥18
Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
Not the right fit? Sign up to receive Lilly Trial Alerts to find out about new trials.
10  Not Yet Enrolling
131  Total Trials
A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Not Yet Enrolling
Conditions: Type 2 diabetes, Healthy volunteers
Drugs: LY3938577, insulin degludec
Age
18-70
Phase
I
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
Not Yet Enrolling
Conditions: Obesity
Drugs: Mazdutide
Age
18-75
Phase
II
SUNRAY-01: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a...
Not Yet Enrolling
Conditions: Non-Small Cell Lung Cancer
Trial Name
SUNRAY-01
Drugs: LY3537982, Pemetrexed, Pembrolizumab, Cisplatin, Carboplatin
Age
≥18
Phase
III
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Withou...
Not Yet Enrolling
Conditions: Type 2 Diabetes
Trial Name
ACHIEVE-5
Drugs: Orforglipron
Age
≥18
Phase
III
A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis
Not Yet Enrolling
Conditions: Multiple Sclerosis
Drugs: Pirtobruitinib
Age
18-55
Phase
II
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity, or Are Overweight With Weight-Related Comorbiditie...
Not Yet Enrolling
Conditions: Obesity
Drugs: Tirzepatide
Age
12-17
Phase
III
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease (AMAY)
Not Yet Enrolling
Conditions: Crohn's Disease
Trial Name
AMAY
Drugs: Mirikizumab
Age
2-17
Phase
III
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
Not Yet Enrolling
Conditions: Ulcerative Colitis
Trial Name
SHINE-2
Drugs: LY3074828
Age
2-17
Phase
III
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Not Yet Enrolling
Conditions: Prostate Cancer
Drugs: Abemaciclib, Darolutamide, LHRH agonist/antagonist
Age
≥18
Phase
I
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-...
Not Yet Enrolling
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADorable-2
Drugs: Lebrikizumab
Age
6-18
Phase
III
52 
Completed Enrollment
131  Total Trials
Pinned
A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]
Completed Enrollment
Conditions: Lipoprotein Disorder
Trial Name
ALPACA
Drugs: LY3819469
Age
≥40
Phase
II
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer (CYCLONE 2)
Completed Enrollment
Conditions: Prostate Cancer
Trial Name
CYCLONE 2
Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Age
≥18
Phase
III
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (postMONARCH)
Completed Enrollment
Conditions: Breast Cancer
Trial Name
postMONARCH
Drugs: Abemaciclib, Fulvestrant
Age
≥18
Phase
III
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (PACT)
Completed Enrollment
Conditions: Advanced Solid Tumor
Trial Name
PACT
Drugs: Ramucirumab, Abemaciclib, Merestinib, LY3300054
Age
≥18
Phase
I
A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS
Completed Enrollment
Conditions: Aicardi Goutieres Syndrome (AGS)
Drugs: Baricitinib
Age
≥6
Phase
III
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Completed Enrollment
Conditions: Ulcerative Colitis
Trial Name
LUCENT 1
Drugs: Mirikizumab, Placebo
Age
18-80
Phase
III
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431)
Completed Enrollment
Conditions: Non-small Cell Lung Cancer
Trial Name
LIBRETTO-431
Drugs: Carboplatin, Cisplatin, Pembrolizumab, Pemetrexed, Selpercatinib
Age
≥18
Phase
III
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Completed Enrollment
Conditions: Medullary Thyroid Cancer
Trial Name
LIBRETTO-531
Drugs: Selpercatinib, Cabozantinib, Vandetanib
Age
≥12
Phase
III
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
Completed Enrollment
Conditions: Alzheimer's Disease
Trial Name
PROSPECT-ALZ
Drugs: LY3372689
Age
60-85
Phase
II
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
Completed Enrollment
Conditions: Overweight, Obesity
Trial Name
SURMOUNT-5
Drugs: Tirzepatide, Semaglutide
Age
≥18
Phase
III
A Study of LY3200882 in Participants With Solid Tumors
Completed Enrollment
Conditions: Advanced Solid Tumor
Drugs: LY3200882
Age
≥18
Phase
I
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Completed Enrollment
Conditions: Ulcerative Colitis
Trial Name
LUCENT 2
Drugs: Mirikizumab, Placebo
Age
18-80
Phase
III
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) (SYNERGY-NASH)
Completed Enrollment
Conditions: NASH (Nonalcoholic Steatohepatitis)
Trial Name
SYNERGY-NASH
Drugs: tirzepatide (LY3298176)
Age
18-80
Phase
II
Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (SURMOUNT-OSA)
Completed Enrollment
Conditions: Obesity
Trial Name
SURMOUNT-OSA
Drugs: Tirzepatide
Age
≥18
Phase
III
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First ...
Completed Enrollment
Conditions: Type 2 Diabetes
Trial Name
QWINT-2
Drugs: LY3209590, Insulin Degludec, Insulin Efsitora Alfa
Age
≥18
Phase
III
A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer (eMonarcHER)
Completed Enrollment
Conditions: Breast Cancer
Trial Name
eMonarcHER
Drugs: Abemaciclib Plus Hormone Therapy
Age
≥18
Phase
III
A Study of LY3561774 in Participants with High Cholesterol and/or High Triglycerides
Completed Enrollment
Conditions: High Cholesterol and/or High Triglycerides
Trial Name
PROLONG-ANG3
Drugs: LY3561774
Age
≥18
Phase
II
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)
Completed Enrollment
Conditions: Obesity, Heart Failure
Trial Name
SUMMIT
Drugs: Tirzepatide
Age
≥40
Phase
III
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor
Completed Enrollment
Conditions: Desmoplastic Small Round Cell Tumor
Trial Name
CAMPFIRE
Drugs: Cyclophosphamide, Ramucirumab, Vinorelbine
Age
12-29
Phase
II
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT...
Completed Enrollment
Conditions: Type 2 Diabetes
Trial Name
SURPASS-CVOT
Drugs: Tirzepatide, Dulaglutide
Age
≥40
Phase
III
A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus
Completed Enrollment
Conditions: Lupus (SLE)
Drugs: LY3361237
Age
18-65
Phase
II
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
Completed Enrollment
Conditions: Alzheimer's Disease
Trial Name
TRAILBLAZER-EXT
Drugs: Donanemab
Age
≥60
Phase
II
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Completed Enrollment
Conditions: Breast Cancer
Drugs: LY2835219, Letrozole, Anastrozole, Tamoxifen, Exemestane
Age
≥18
Phase
I
A Study of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia
Completed Enrollment
Conditions: Dyslipidemia
Drugs: LY3875383
Age
18-70
Phase
I
A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants
Completed Enrollment
Conditions: Alzheimer's Disease
Drugs: LY3372993
Age
18-85
Phase
I
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
Completed Enrollment
Conditions: Breast Cancer, Non-Small Cell Lung Cancer
Drugs: Abemaciclib, Pembrolizumab
Age
≥18
Phase
I
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
Completed Enrollment
Conditions: Neuroblastoma
Drugs: LY3295668 Erbumine, Topotecan, Cyclophosphamide
Age
2-21
Phase
I
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma (ANNOUNCE)
Completed Enrollment
Conditions: Soft Tissue Sarcoma
Trial Name
ANNOUNCE
Drugs: Olaratumab/Placebo, Doxorubicin
Age
≥18
Phase
III
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer (monarcHER)
Completed Enrollment
Conditions: Breast Cancer
Trial Name
monarcHER
Drugs: Abemaciclib (LY2835219), Trastuzumab, Fulvestrant, Standard of care chemotherapy
Age
≥18
Phase
II
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (MONARCH plus)
Completed Enrollment
Conditions: Breast Cancer
Trial Name
MONARCH plus
Drugs: Abemaciclib, Anastrozole, Letrozole, Fulvestrant
Age
≥18
Phase
III
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (Next MONARCH 1)
Completed Enrollment
Conditions: Breast Cancer
Trial Name
Next MONARCH 1
Drugs: Abemaciclib, Tamoxifen, Prophylactic Loperamide
Age
≥18
Phase
II
A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
Completed Enrollment
Conditions: Type 2 diabetes
Trial Name
SURPASS-SWITCH-2
Drugs: LY3298176
Age
≥18
Phase
IV
A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes...
Completed Enrollment
Conditions: Type 2 diabetes
Trial Name
QWINT-4
Drugs: LY3209590, Insulin Lispro, Insulin Glargine, Insulin Efsitora Alfa
Age
≥18
Phase
III
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER)
Completed Enrollment
Conditions: Non-Small Cell Lung Cancer
Trial Name
JUNIPER
Drugs: Abemaciclib, Erlotinib
Age
≥18
Phase
III
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Completed Enrollment
Conditions: Advanced Solid Tumor
Drugs: LY3410738
Age
≥18
Phase
I
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Completed Enrollment
Conditions: Leukemia - AML, Leukemia - CML, Myelodysplastic Syndrome
Trial Name
I9Y-OX-JDHB
Drugs: LY3410738
Age
≥18
Phase
I
A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (RESOLUTION-1)
Completed Enrollment
Conditions: Rheumatoid Arthritis
Trial Name
RESOLUTION-1
Drugs: Peresolimab
Age
≥18
Phase
II
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Completed Enrollment
Conditions: Alzheimer's Disease
Trial Name
TRAILBLAZER-ALZ 2
Drugs: Donanemab
Age
60-85
Phase
III
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin fo...
Completed Enrollment
Conditions: Type 2 Diabetes
Trial Name
QWINT-1
Drugs: LY3209590, Insulin Glargine, Insulin Efsitora Alfa
Age
≥18
Phase
III
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata (BRAVE-AA2)
Completed Enrollment
Conditions: Alopecia Areata (Hair Loss)
Trial Name
BRAVE-AA2
Drugs: Baricitinib, Placebo
Age
18-70
Phase
III
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)
Completed Enrollment
Conditions: Breast Cancer
Trial Name
monarchE
Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Age
≥18
Phase
III
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1)
Completed Enrollment